1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- Author
-
Horwitz, Steven, O'Connor, Owen A, Pro, Barbara, Illidge, Tim, Fanale, Michelle, Advani, Ranjana, Bartlett, Nancy L, Christensen, Jacob Haaber, Morschhauser, Franck, Domingo-Domenech, Eva, Rossi, Giuseppe, Kim, Won Seog, Feldman, Tatyana, Lennard, Anne, Belada, David, Illés, Árpád, Tobinai, Kensei, Tsukasaki, Kunihiro, Yeh, Su-Peng, Shustov, Andrei, Hüttmann, Andreas, Savage, Kerry J, Yuen, Sam, Iyer, Swaminathan, Zinzani, Pier Luigi, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Trümper, Lorenz, Aboulafia, David, Advani, Ranjana, Alpdogan, Onder, Ando, Kiyoshi, Arcaini, Luca, Baldini, Luca, Bellam, Naresh, Bartlett, Nancy, Belada, David, Yehuda, Dina Ben, Benedetti, Fabio, Borchman, Peter, Bordessoule, Dominique, Brice, Pauline, Briones, Javier, Caballero, Dolores, Carella, Angelo Michele, Chang, Hung, Cheong, June Weon, Cho, Seok-Goo, Choi, Ilseung, Choquet, Sylvain, Colita, Andrei, Congui, Angela Giovanna, D'amore, Francesco, Dang, Nam, Davison, Kelly, de Guibert, Sophie, Brown, Peter de Nully, Delwail, Vincent, Demeter, Judit, di Raimondo, Francesco, Do, Young Rok, Domingo, Eva, Douvas, Michael, Dreyling, Martin, Ernst, Thomas, Fanale, Michelle, Fay, Keith, Feldman, Tatyana, Ferrero, Silvia Fernandez, Flinn, Ian Winchester, Forero-Torres, Andres, Fox, Christopher, Friedberg, Jonathan, Fukuhara, Noriko, Garcia-Marco, Jose, Cruz, Jorge Gayoso, Codina, Jose Gomez, Gressin, Remy, Grigg, Andrew, Gurion, Ronit, Christensen, Jacob Haaber, Haioun, Corinne, Hajek, Roman, Hanel, Mathias, Hatake, Kiyohiko, Hensen, Robert, Horowitz, Netanel, Horwitz, Steven, Huttmann, Andreas, Illes, Arpad, Illidge, Tim, Ishizawa, Kenichi, Islas-Ohlmayer, Miguel, Jacobsen, Eric, Janakiram, Murali, Jurczak, Wojciech, Kaminski, Mark, Kato, Koji, Kim, Won Seog, Kirgner, Ilya, Iyer, Swaminathan, Kuo, Ching-Yuan, Lazaroiu, Mihaela Cornelia, Du, Katell Le, Lee, Jong-Seok, LeGouill, Steven, Lennard, Anne, LaRosee, Paul, Levi, Itai, Link, Brian, Maisonneuve, Herve, Maruyama, Dai, Mayer, Jiri, McCarty, John, McKay, Pam, Minami, Yosuke, Mocikova, Heidi, Morra, Enrica, Morschhauser, Franck, Munoz, Javier, Nagai, Hirokazu, O'Connor, Owen, Opat, Stephen, Pettengell, Ruth, Pezzutto, Antonio, Pfreundschuh, Michael, Pluta, Andrzej, Porcu, PierLuigi, Pro, Barbara, Quach, Hang, Rambaldi, Alessandro, Renwick, William, Reyes, Ruben, Izquierdo, Antonia Rodriguez, Rossi, Giuseppe, Ruan, Jia, Rusconi, Chiara, Salles, Gilles, Santoro, Armando, Sarriera, Jose, Savage, Kerry, Shibayama, Hirohiko, Shustov, Andrei, Suh, Cheolwon, Sureda, Anna, Tanimoto, Mitsune, Taniwaki, Masafumi, Tilly, Herve, Tobinai, Kensei, Trneny, Marek, Trumper, Lorenz, Tsukamoto, Norifumi, Tsukasaki, Kunihiro, Vitolo, Umberto, Walewski, Jan, Weidmann, Eckhart, Wilhelm, Martin, Witzens-Harig, Mathias, Yacoub, Abdulraheem, Yamamoto, Kazuhito, Yeh, Su-Peng, Yoon, Sung-Soo, Yuen, Sam, Yun, Hwan Jung, Zain, Jasmine, and Zinzani, Pier Luigi
- Abstract
Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.
- Published
- 2019
- Full Text
- View/download PDF